Skip to Main Content

Earlier this year, Food and Drug Administration Commissioner Robert M. Califf proposed something radical: that private health care insurance companies (payers) should participate in clinical research on FDA-approved drugs.

This challenges the prevailing convention that only drug developers conduct such studies — and it’s an idea worth considering. While there is no major precedent for payers to participate, the move could augment clinical evidence and enhance patient-centric care across various therapeutic areas, including in Alzheimer’s treatment.

advertisement

Drawing from my experience in developing precision medicine protocols for biotech drugs, I am aware of the complexities in implementing these strategies into clinical development or post-approval settings. Nevertheless, navigating these challenges is essential — which is why Klaritos, where I am CEO, is building a precision medicine platform for conducting payer-participating trials on FDA-approved drugs. Despite extensive investments by biotech and pharma companies in clinical trials, unresolved questions about the efficacy or safety of numerous approved drugs persist. Bringing payers into clinical research could help solve these problems.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.